A RESOLUTION AUTHORIZING THE CITY MAYOR, HONORABLE MA. JOSEFINA G. BELMONTE, TO ENTER INTO A MULTILATERAL AGREEMENT WITH ASTRazeneca PHARMACEUTICALS PHILIPPINES, INC., THE REPUBLIC OF THE PHILIPPINES (ACTING THROUGH THE NATIONAL TASK FORCE AGAINST COVID-19), AND OTHER PARTICIPATING LOCAL GOVERNMENT UNITS FOR THE ADVANCE PURCHASE OF 750,000 DOSES OF ASTRazeneca COVID-19 VACCINES (AZD1222) AND ALLOWING THE USE OF PORTION OF THE EXISTING ONE BILLION PESOS (PHP1,000,000,000.00) APPROPRIATION INTENDED FOR COVID-19 VACCINES IN THE NECESSARY AMOUNT.

Introduced by Councilors FRANZ S. PUMAREN, DOROTHY A. DELARMENTE, M.D. and DIORELLA MARIA G. SOTTO-ANTONIO.


WHEREAS, on March 9, 2020, the President declared a State of National Health Emergency due to the COVID-19 pandemic. On March 12, 2020, the President declared Community Quarantine over Metro Manila and modified forms of quarantine eventually covered the entire country;
4th Special Session

Res. No. SP-8434, S-2021
Page -2- PR21CC-847

WHEREAS, on March 13, 2020, the City Council declared Quezon City to be under a State of Calamity due to COVID-19 pandemic;

WHEREAS, as of January 4, 2021, the COVID-19 virus has infected at least 85 million people worldwide, including 477,807 Filipinos. The virus has killed at least 1.8 million people worldwide, including 9,257 Filipinos;

WHEREAS, the nations of the world have focused their efforts on finding vaccines to combat this deadly disease. These nationally-supported endeavors included AstraZeneca UK, which partnered with Oxford University to rapidly clinically evaluate and scale-up global manufacturing of its COVID-19 vaccine known as AZD1222 (the "AstraZeneca Vaccine");

WHEREAS, on 30 December 2020, the government of the United Kingdom announced its approval of the AstraZeneca Vaccine. Through its Philippine subsidiary, AstraZeneca Pharmaceuticals Philippines, Inc., AstraZeneca offered the Vaccine to the Philippine government at significantly lower cost compared to the vaccines of its competitors. Further, in contrast to its competitors, which require ultra-subzero storage, the AstraZeneca Vaccine may be stored in a normal refrigerator at temperatures of 2 to 8 degrees Celsius. This will further reduce the cost of distributing the Vaccine;

WHEREAS, the Republic of the Philippines, through the National Task Force Against COVID-19 (NTF), has commenced negotiating with AstraZeneca to acquire millions of doses of the Vaccine for immediate distribution. Aside from the doses to be acquired by the national government, AstraZeneca and NTF have arranged to give interested local governments, including Quezon City, the opportunity to directly purchase and acquire their own doses of the AstraZeneca Vaccine. In this regard, AstraZeneca and NTF propose that the City enter into a Multilateral Agreement with AstraZeneca, NTF, and purchasing local government units, including Quezon City. Under this Agreement, the participating LGUs undertake to purchase specified numbers of doses from AstraZeneca, and NTF undertakes to expedite the required national government approvals;

WHEREAS, the President’s Executive Order No. 121, S. 2020, authorizes the Food and Drug Authority (FDA) to issue an Emergency Use Authorization for COVID-19 Vaccines. AstraZeneca has informed the Quezon City Government that its application for an Emergency Use Authorization for the Vaccine is pending before the FDA;
WHEREAS, Section 5.14 of the Implementing Guidelines of Republic Act No. 11494 ("Bayanihan 2"), as well as the Government Procurement Policy Board Resolution No. 03-2020, authorize the emergency procurement of COVID-19 vaccines;

WHEREAS, Section 6(e) of Republic Act No. 11332, otherwise known as "The Mandatory Reporting of Notifiable Diseases and Health Events of Public Health Concern Act," provides that local governments have the authority to conduct and enforce disease surveillance and response systems, epidemic/outbreak and epidemiologic investigations, and rapid containment, quarantine and isolation, disease prevention, and control measures;

WHEREAS, based on Section 16 of the Local Government Code of 1991, the City has the implied power to do all things necessary, appropriate or incidental to govern efficiently and effectively, promote general welfare, promote health and safety, maintain peace and order, and preserve the comfort and convenience of their inhabitants;

WHEREAS, Section 458 (a)(1)(iv) of Republic Act No. 7160 or the Local Government Code of 1991, provides that the City Council may adopt measures to protect the inhabitants of the City from the harmful effects of natural disasters and calamities;

WHEREAS, on August 3, 2020, the Quezon City Council, through a resolution, strongly urged the Honorable City Mayor to allocate One Billion Pesos (Php1,000,000,000.00) from the City’s annual budget for 2021 to cover expenses for the COVID-19 vaccines in Quezon City

NOW, THEREFORE,

BE IT RESOLVED BY THE CITY COUNCIL OF QUEZON CITY IN A SPECIAL SESSION ASSEMBLED, to authorize, as it does hereby authorize, the City Mayor, Honorable Ma. Josefinha G. Belmonte, to enter into a Multilateral Agreement with AstraZeneca Pharmaceuticals Philippines, Inc., the Republic of the Philippines (acting through the National Task Force Against COVID-19), and other participating local government units for the advance purchase of 750,000 doses of AstraZeneca COVID-19 Vaccines (AZD1222) and allowing the use of portion of the existing One Billion Pesos (Php1,000,000,000.00) appropriation intended for COVID-19 vaccines in the necessary amount.
RESOLVED FURTHER, that a copy of the subject Multilateral Agreement shall form an integral part of this Resolution.

ADOPTED: January 5, 2021.

GIAN G. SOTTO
City Vice Mayor
Presiding Officer

ATTESTED:

Atty. JOHN THOMAS S. ALFEROS III
City Government Dept. Head III

CERTIFICATION

This is to certify that this Resolution was Certified Urgent by the City Mayor, was APPROVED by the City Council on Second Reading during its 4th Special Session on January 5, 2021 and was CONFIRMED on the same date.

Atty. JOHN THOMAS S. ALFEROS III
City Government Dept. Head III